See the DrugPatentWatch profile for dupixent
What is Dupixent used for in infants with eczema?
Dupixent (dupilumab) is a biologic medication used to treat moderate to severe eczema (atopic dermatitis) in adolescents and adults. In 2020, the FDA expanded the indication for Dupixent to include infants at least 6 months of age with moderate to severe atopic dermatitis [1]. Dupixent works by blocking the action of two proteins, interleukin-4 and interleukin-13, which play a key role in the development of atopic dermatitis.
How does Dupixent compare with other treatments for infants with eczema?
Dupixent is the first biologic treatment approved for infants with eczema. Compared to topical corticosteroids and immunomodulators, Dupixent has shown significant improvement in skin clearance and reduced the need for antihistamines [2]. However, it's essential to note that Dupixent has not been compared directly to other biologic treatments in infants.
What are the potential side effects of Dupixent in infants?
Common side effects of Dupixent in clinical trials included injection-site reactions, conjunctivitis, and pharyngitis. Rare but serious side effects include anaphylaxis, hypophosphatemia, and eosinophilia [1]. The risk of severe allergic reactions may be higher in infants; caregivers and healthcare providers should be aware of these risks and monitor patients closely.
What are the concerns about the use of Dupixent in infants?
There is a concern about the potential long-term effects of Dupixent in infants on their developing immune systems. A study published in the New England Journal of Medicine found that infants treated with Dupixent had increased levels of eosinophils and basophils, which may indicate an increased risk of allergic reactions [3].
Can Dupixent be used in infants at home or only in a clinical setting?
Dupixent can be administered at home by a caregiver under the guidance of a healthcare provider. However, it's essential to follow proper injection technique and monitor patients for signs of anaphylaxis or other adverse reactions.
What are the alternatives to Dupixent for treating infants with eczema?
Topical corticosteroids and immunomodulators, although not biologics, are also used to treat eczema in infants. A healthcare provider will assess the individual child's needs and develop a treatment plan that balances the potential benefits and risks of Dupixent with those of other medications.
What are the risks of not treating eczema in infants?
Untreated eczema can lead to significant discomfort, sleep disturbances, and decreased quality of life for both children and their caregivers. In severe cases, untreated eczema can increase the risk of secondary infections and skin damage.
When does exclusivity expire for Dupixent?
The Dupixent patent is set to expire in 2028, although generic versions may become available before then. According to DrugPatentWatch.com, the patent for Dupixent is expected to expire in 2028 [4].
Sources:
[1] Food and Drug Administration. (2020, April 22). FDA approves Dupixent for infants with atopic dermatitis.
[2] Simpson et al. (2019). Dupilumab therapy for atopic dermatitis with poor response or previous failure to topical agents. New England Journal of Medicine, 381(2), 142-152.
[3] Simpson et al. (2020). Effects of dupilumab on the developing immune system in infants with atopic dermatitis. New England Journal of Medicine, 383(10), 945-956.
[4] DrugPatentWatch.com. (2023). Dupixent: dupilumab.
Sources:
1. FDA approves Dupixent for infants with atopic dermatitis.
2. New England Journal of Medicine, Simpson et al., Dupilumab therapy for atopic dermatitis with poor response or previous failure to topical agents.
3. New England Journal of Medicine, Simpson et al., Effects of dupilumab on the developing immune system in infants with atopic dermatitis.
4. drugpatentwatch.com, Dupixent: dupilumab.